The prevalence of sarcoidosis, or the proportion of people with the condition in a population, has roughly doubled over the past 30 years in a region in Norway, a large population-based study shows, and the incidence of sarcoidosis, that is, the number of new cases within a given time,…
News
April has officially been recognized as Sarcoidosis Awareness Month in the U.S., marking a significant milestone for the community and its advocates, according to the Foundation for Sarcoidosis Research (FSR) — which also celebrates its 25th anniversary this year. The recognition by the U.S. Congress was spearheaded by Danny…
More than two dozen mutations that seem to increase the risk of developing sarcoidosis were identified in a new study. Notably, 17 of the 28 mutations hadn’t been linked to the inflammatory disease. Higher genetically predicted body mass index (BMI) and higher levels of several proteins involved in inflammation…
The findings of a new preclinical study in pulmonary sarcoidosis are lending support to the therapeutic potential of efzofitimod, a treatment candidate from Atyr Pharma now being tested in a Phase 3 clinical trial. The researchers found that a protein called HARS-WHEP — whose activity is mimicked by…
Nearly 1 in 10 people with pulmonary sarcoidosis also have heart involvement, or cardiac sarcoidosis, at the time of their initial diagnosis with the rare inflammatory disease occurring in the lungs, according to a study in Japan. Further, another 3.8% of patients subsequently develop cardiac sarcoidosis, the data…
The Foundation for Sarcoidosis Research (FSR) is partnering with Walgreens and Cedars-Sinai to provide free N95 face masks at two locations in Los Angeles, with the goal of helping members of the community protect their lungs following January’s wildfires. Exposure to fine particulate matter from soot and ash in…
April is Sarcoidosis Awareness Month, and this year’s theme, as chosen by the Foundation for Sarcoidosis Research (FSR), is “Facing Sarcoidosis Together” — which seeks to recognize the unique ways in which community, support, and advocacy can help patients navigate their disease. “Living with sarcoidosis presents significant challenges,…
Enrollment is complete in the dose-finding phase of a Phase 1b/2b clinical trial evaluating Xentria’s investigational therapy XTMAB-16 in adults with pulmonary sarcoidosis, and screening for the next phase is expected to start next fall. The Phase 1b/2 study (NCT05890729) enrolled 39 pulmonary sarcoidosis patients in four…
Atyr Pharma and the U.S. Food and Drug Administration (FDA) have aligned on the specific main outcome analysis of the ongoing Phase 3 clinical trial that’s testing the company’s investigational therapy efzofitimod in people with pulmonary sarcoidosis. Based on FDA feedback during a recent type C meeting,…
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to better understand the real-world lived experiences of people in the U.S. with rare diseases. Living Rare, the first large-scale study of its kind in the U.S., seeks to capture the…
Recent Posts
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF
- A holiday gift guide for your loved one with sarcoidosis
- FSR gathers global leaders to drive progress in sarcoidosis research
- New genetic clues connect sarcoidosis with lung cancer risk
- When patients and caregivers swap roles, empathy usually follows
- Underdiagnosis of cardiac sarcoidosis leaves people at risk
- Repurposing drugs may improve survival for people with sarcoidosis
- Few with sarcoidosis see lung specialist within a year of diagnosis